ARIA

We Continue To Think Ariad Is Fairly Valued, Says Cowen; Sees 28% Downside

In a research report sent to investors, Cowen analyst Phil Nadeau maintained a Market Perform rating on Ariad Pharmaceuticals (NASDAQ:ARIA) with a $4.50 …

Jason Cohen — January 15, 2015, 8:45 AM EDT

J.P. Morgan Comments On Ariad Following 2015 Strategic Update

J.P.

Jason Cohen — January 13, 2015, 5:34 PM EDT

ARIA: ARIAD Announces Key Strategic Objectives for 2015 Expected to Lead Company to Profitability in Three Years

Three New Clinical Trials to Begin in 2015, including a Global, Randomized Trial of Iclusig vs. Nilotinib in Second-Line CML CAMBRIDGE, Mass.

Corey Williams — January 13, 2015, 9:49 AM EDT

Ariad Pharmaceuticals: Optimized Iclusig Dosing Could Be Key To Sales, Says H.C. Wainwright

In a research report issued this morning, H.C.

Ben Mahaney, Editor — January 7, 2015, 10:53 AM EDT

J.P. Morgan Comments On Ariad Pharmaceuticals Following Update On Iclusig Trial Design

J.P.

Ben Mahaney, Editor — January 6, 2015, 1:38 PM EDT

Shares Of Ariad Are Undervalued And Present Upside, Says H.C. Wainwright

In a research report published today, H.C.

Editor Ben Weinberg — November 6, 2014, 5:23 PM EDT

William Blair Remains Positive On Ariad On The Heels Of Favorable PRAC Review For Iclusig

In a research report issued today, William Blair analyst Y Katherine Xu maintained an Outperform rating on Ariad Pharmaceuticals (NASDAQ:ARIA) with a $12 price …

Ben Mahaney, Editor — October 10, 2014, 6:11 PM EDT